A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum.

Trial Profile

A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Docetaxel (Primary) ; Capecitabine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 May 2009 Primary endpoint identified as (objective tumour response) as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 May 2009 Planned number of patients changed from 39 to 2 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top